1. Lim JL, Lin CJ, Huang CC, Chang LC*. Curcumin-derived carbon quantum dots: dual actions in mitigating tau hyperphosphorylation and amyloid beta aggregation. Colloids Surf B Biointerfaces 2024; 234: 113676.

2. Chiang YH^, Cheng CN^, Chuang PJ, Chen YC, Chen YJ, Kuo CH*, Lin SW*, Chang LC*. Enhancing the identification of voriconazole-associated hepatotoxicity by targeted metabolomics. Int J Antimicrob Agents 2024; 63: 107028.

3. Cheng CA^, Jiang AL^, Liu YR, Chang LC*. Investigation of immunogenicity assessment of biosimilar monoclonal antibodies in the United States. Clin Pharmacol Ther 2023; 114: 1274-84.

4. Liu YH, Chen YS^, Tseng T^, Jiang ML^, Gau CS, Chang LC*. Regulatory considerations for generic products of non-biological complex drugs. J Food Drug Anal 2023; 31: 20-31.

5. Huang YJ, Chao WY, Wang CC, Chang LC*. Orphan drug development: the impact of regulatory and reimbursement frameworks. Drug Discov Today 2022; 27: 1724-32.

6. Hsiang NC, Huang WF, Gau CS, Tsai TW, Chang LC*. The impact of The Rare Disease and Orphan Drug Act in Taiwan. J Food Drug Anal 2021; 29: 717-25.

7. Jiang AL, Breder CD, Chang LC*. Investigation of factors associated with immunogenicity labeling updates and characteristics of Biologics License Applications. Clin Pharmacol Ther 2021; 110: 1381-8.

8. Huang JW, Kuo CH, Kuo HC, Shih JY, Tsai TW, Chang LC*. Cell metabolomics analyses revealed a role of altered fatty acid oxidation in neurotoxicity pattern difference between nab-paclitaxel and solvent-based paclitaxel. PLoS One 2021; 16: e0248942.

9. Huang JW, Kuo CH, Kuo HC, Shih JY, Tsai TW, Chang LC*. Differences in fatty acid oxidation between nab-paclitaxel- and solvent-based paclitaxel-treated A549 cells based on metabolomics. ACS Omega 2021; 6: 5138-45.

10. Liou JS, Chang LC*. Investigation of quality review issues and the association with application characteristics for new drug applications in first-cycle reviews. Regul Toxicol Pharmacol 2019; 108: 104448.

11. Chepyala D^, Kuo HC^, Su KY, Liao HW, Wang SY, Chepyala SR, Chang LC*, Kuo CH*. Improved dried blood spot-based metabolomics analysis by a postcolumn infused-internal standard assisted liquid chromatography-electrospray ionization mass spectrometry method. Anal Chem 2019; 91: 10702-12.

12. Chang LC*. The biosimilar pathway in the USA: an analysis of the innovator company and biosimilar company perspectives and beyond. J Food Drug Anal 2019; 27: 671-8.

13. Breder CD*, VanHeusen M, Chang LC. Correlates of time to approval and other clinical development periods. Drug Discov Today 2019; 24: 1871-6.

14. Hsu YL^, Chen CC^, Lin YT, Wu WK, Chang LC, Lai CH, Wu MS, Kuo CH*. Evaluation and optimization of sample handling methods for quantification of short-chain fatty acids in human fecal samples by GC-MS. J Proteome Res 2019; 18: 1948-57.

15. Chang LC, Vanheusen M, Fang X, Breder CD*. Identification of factors associated with first-cycle drug approval rates and regulatory outcomes for new drug applications. Pharmacol Res 2019; 139: 166-72.

16. Chang LC, Chang CC, Chen PL, Wang SH, Chen YH, Tsai YH, Shih SR, Chiu WY, Fann CSJ*, Yang WS*, Chang TC*. Thyrotropin receptor antibodies and a genetic hint in antithyroid drug-induced adverse drug reactions. Expert Opin Drug Saf 2018; 17: 775-84.

17. Chang LC*, Colonna TE. Recent updates and challenges on the regulation of precision medicine: the United States in perspective. Regul Toxicol Pharmacol 2018; 96: 41-7.

18. Chang LC, Huang CF, Lai MS, Shen LJ, Wu FLL, Cheng WF*. Prognostic factors in epithelial ovarian cancer: a population-based study. PLoS One 2018; 13: e0194993.

19. Chang LC, Mahmood R, Qureshi S, Breder CD*. Patterns of use and impact of standardised MedDRA query analyses on the safety evaluation and review of new drug and biologics license applications. PLoS One 2017; 12: e0178104.

20. Chang LC, Kang JJ, Gau CS*. Development of the risk-based, phased-in approach for the international harmonization of the regulation of container closure systems for drugs in Taiwan. Regul Toxicol Pharmacol 2016; 77: 252-6.

21. Chang LC, Kang JJ, Gau CS*. The evolution and challenges for the international harmonization of the regulation of pharmaceutical excipients in Taiwan. Regul Toxicol Pharmacol 2015; 73: 947-52.

22. Chang LC*, Gau CS. Statistics, quality review issues, and beyond for generic drug applications in Taiwan. Ther Innov Regul Sci 2013; 47: 670-7.

23. Chang LC, Huang KC, Wu YW, Kao HL, Chen CL, Lai LP, Hwang JJ, Yang WS*. The clinical implications of blood adiponectin in cardiometabolic disorders. J Formos Med Assoc 2009; 108: 353-66.

24. Chang LC, Chang YY, Gau CS*. Interfacial properties of Pluronics and the interactions between Pluronics and cholesterol/DPPC mixed monolayers. J Colloid Interface Sci 2008; 322: 263-73.

25. Chiu TC, Chang LC, Chiang CK, Chang HT*. Determining estrogens using surface-assisted laser desorption/ionization mass spectrometry with silver nanoparticles as the matrix. J Am Soc Mass Spectrom 2008; 19: 1343-6.

26. Chang LC, Chiu TC, Lee SS, Kuo CH, Chang TC*. Simultaneous separation of four types of steroid hormones by micellar electrokinetic chromatography with cetyltrimethylammonium bromide. J Chin Chem Soc 2008; 55: 594-605.

27. Lu JY, Huang KC, Chang LC, Huang YS, Chi YC, Su TC, Chen CL, Yang WS*. Adiponectin: a biomarker of obesity-induced insulin resistance in adipose tissue and beyond. J Biomed Sci 2008; 15: 565-76.

28. Chang LC, Chang HT, Sun SW*. Cyclodextrin-modified microemulsion electrokinetic chromatography for separation of α-, γ-, δ-tocopherol and α-tocopherol acetate. J Chromatogr A 2006; 1110: 227-34.

29. Chang LC, Sun SW*. Micellar electrokinetic chromatography for separation of a mixture of coptis alkaloids, scute flavonoids, and rhubarb anthraquinones and bianthrones. J Pharm Biomed Anal 2006; 40: 62-7.

30. Chang LC, Lin CY, Kuo MW, Gau CS*. Interactions of Pluronics with phospholipid monolayers at the air-water interface. J Colloid Interface Sci 2005; 285: 640-52.